STOCK TITAN

Lucid Diagnostics (LUCD) SEC Filings, Aug-Oct 2025

LUCD NASDAQ

Lucid Diagnostics Inc. filings document a commercial-stage medical diagnostics issuer focused on esophageal precancer detection, its public-company governance, and its capital structure. Its 8-K reports disclose operating results and business updates for EsoGuard and EsoCheck, Regulation FD communications, completed common stock offerings, shelf registration statement references, proceeds for working capital and general corporate purposes, and related exhibits.

Proxy materials cover annual meeting matters, director elections, board classification, and stockholder voting. Other material-event filings address board appointments, non-employee director compensation arrangements, indemnification agreements, and governance rights associated with holders of the company’s convertible secured promissory notes due 2029.

Rhea-AI Summary

John R. Palumbo, a director of Lucid Diagnostics Inc. (LUCD), filed an Initial Statement of Beneficial Ownership reporting direct ownership of 47,857 shares of common stock. The transaction date requiring the filing is 09/22/2025. The Form 3 was signed by Michael A. Gordon by power of attorney on 10/07/2025. No derivative securities or additional holdings were reported on this form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.19%
Tags
insider
-
Rhea-AI Summary

Lucid Diagnostics Inc. disclosed that under the agreements governing the sale of its Convertible Notes, the note holders have the collective right to designate one individual to be appointed to the company’s board of directors. This appointment right is subject to certain limitations and to the policies and procedures of the company’s nominating and corporate governance committee. The filing text is brief and focuses solely on the governance right tied to the Convertible Notes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
-
Rhea-AI Summary

Lucid Diagnostics, Inc. disclosed a material event on a Form 8-K filed on September 11, 2025. The filing references a preliminary prospectus supplement dated September 9, 2025 and a final prospectus supplement dated September 10, 2025, and attaches a press release announcing the closing as Exhibit 99.1. The document is signed by Dennis McGrath, Chief Financial Officer. The filing indicates a Regulation FD disclosure checkbox and an Inline XBRL cover page data file are included.

The short filing confirms paperwork and a press release related to a completed transaction or offering, but it does not disclose financial terms, the size of any offering, counterparties, or operational impacts. The available content documents the administrative close and supporting prospectus supplements without quantitative details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.90%
Tags
current report
Rhea-AI Summary

Prospectus supplement excerpts for Lucid Diagnostics, Inc. (LUCD) outline a securities offering structure and select pro forma balance sheet items. The underwriting discount is shown as $0.0575 per share totaling $1,437,500, leaving proceeds to the issuer before expenses of $0.9425 per share or $23,562,500. The underwriting allocation lists BTIG LLC: 11,875,000 shares and Maxim Group LLC: 1,250,000 shares toward a 25,000,000-share total. Pro forma capitalization items include Series B and B-1 preferred: 54,419 shares (presented with $54,419), common shares outstanding of 101,826,788, and additional paid-in capital shown as $201,013 (historical) and $224,391 (pro forma). The excerpt contains many table-of-contents entries and procedural disclosures but omits complete line-item values for several fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.90%
Tags
prospectus
-
Rhea-AI Summary

Lucid Diagnostics entered into an underwriting agreement to sell common stock to the public at $1.00 per share, with the underwriters purchasing shares from the company at $0.9425 per share, representing a $0.0575 underwriting discount. The company granted the underwriters a 30-day option to buy up to 3,750,000 additional shares at the public offering price less the underwriting discount. Lucid agreed to reimburse certain underwriting expenses, including legal fees, up to $100,000, and to indemnify the underwriters for specified liabilities under the Securities Act.

The filing cites an underlying registration statement originally filed on November 25, 2022 and declared effective December 6, 2022, and notes a preliminary prospectus supplement dated September 9, 2025 filed that same day; a final prospectus supplement will be filed under Rule 424. The Underwriting Agreement is subject to customary closing conditions, representations, warranties and covenants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.69%
Tags
current report
-
Rhea-AI Summary

Lucid Diagnostics, Inc. (LUCD) filed a 424B5 prospectus supplement describing an offering of debt securities alongside disclosure of its capital structure as of June 30, 2025. The filing shows 54,419 shares of Series B and Series B-1 convertible preferred stock outstanding and 101,826,788 common shares issued and outstanding. The company reports $201,013 in additional paid-in capital and names BTIG LLC and Maxim Group LLC as underwriters. Several offering-line items (public offering price, underwriting discount, proceeds to issuer, and per-share net tangible book value figures) are present as placeholders or not populated in the provided text.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.69%
Tags
prospectus
Rhea-AI Summary

Lucid Diagnostics director Dennis Matheis reported a purchase of company common stock. The Form 4 discloses a purchase of 100,000 shares on 08/20/2025 at a weighted-average price of $1.0184 per share, with transaction prices ranging from $1.0085 to $1.0286. After the purchase, the reporting person beneficially owned 665,443 shares. The filing indicates the reporting person is a director and the Form 4 was filed by one reporting person. The reporting person authorized Michael A. Gordon to sign the Form 4 by power of attorney.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
insider
-
Rhea-AI Summary

Lucid Diagnostics Inc. announced it furnished a press release reporting financial results and a business update for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The company disclosed that the information under Items 2.02 and 7.01, including the exhibit, is furnished and shall not be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. The filing identifies the registrant as Lucid Diagnostics Inc., trading as LUCD on The Nasdaq Stock Market, and indicates the company qualifies as an emerging growth company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
current report
-
Rhea-AI Summary

Lucid Diagnostics (LUCD) is a commercial-stage cancer-prevention diagnostics company selling the EsoGuard test with EsoCheck sampling. For the three and six months ended June 30, 2025 the company recognized $1.16 million and $1.99 million of revenue, respectively, while reporting a net loss attributable to common stockholders of $7.9 million for the quarter and $43.9 million for the six months. Operating activities used $23.0 million of cash in the first half of 2025, leaving $31.1 million of cash and approximately $4.4 million of working capital as of June 30, 2025.

Key balance sheet and financing items include total assets of $38.7 million, stockholders' equity of $7.9 million, and Senior Secured Convertible Notes with $21.975 million face value carried at fair value of $25.3 million (conversion price $1.00; 12% stated interest). Management discloses substantial doubt about going concern absent increased reimbursement, revenue growth or additional financing. Recent developments include two equity raises in March and April 2025 netting ~$31.0 million, an ATM up to $25.0 million, Highmark coverage in New York effective May 26, 2025, MolDx LCD reconsideration (CAC on Sept 4, 2025), multiple peer-reviewed publications, and an $8.0 million NIH R01 award to CWRU investigators.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
quarterly report

FAQ

How many Lucid Diagnostics (LUCD) SEC filings are available on StockTitan?

StockTitan tracks 49 SEC filings for Lucid Diagnostics (LUCD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Lucid Diagnostics (LUCD)?

The most recent SEC filing for Lucid Diagnostics (LUCD) was filed on November 12, 2026.